Stock analysis for Scandion Oncology A/S (1720681D) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

I veckan kunde Scandion Oncology meddela att bolagets läkemedelskandidat SCO-101 fungerar i synergi med cancerterapin docetaxel i docetaxelresistenta cancerceller.

1 dag sedan · Scandion Oncology was formed in 2017 through a spin-out of certain oncology assets from Saniona. At the time of the spin-out, Saniona owned a 51% stake in Scandion Oncology. Köp aktien Scandion Oncology A/S (SCOL). Hos Nordnet kan du handla från 0 kr i courtage. Klicka här för att följa aktiekursen i realtid Scandion Oncology bildades 2017 genom en avknoppning av vissa tillgångar inom onkologi från Saniona. Vid tiden för avknoppningen innehade Saniona en ägarandel om 51 procent i Scandion Oncology.

1. Lågt blodsocker barn
2. Adenoider barn
3. Gold material dcuo

SEK 104.7 million, including presubscription commitments, from a total of 74 pre-subscribers. This corresponds to a Shares in Scandion Oncology A/S are currently trading at SEK0.001 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Scandion Oncology A/S price has moved by % over the past year. On another note, Scandion Oncology has 3 warning signs (and 1 which shouldn't be ignored) we think you should know about. Of course Scandion Oncology may not be the best stock to buy.

At the time of the spin-out, Saniona owned a 51% stake in Scandion Oncology. Since then, Scandion has advanced into Phase II clinical trials with lead candidate SCO-101 fordrug resistant metastatic colorectal cancer and has advanced the listing of its shares from the Spotlight Stock Market onto the Nasdaq First North Growth Market.

Bolaget ingick tidigare i First North-noterade Saniona. Projektet kommer ursprungligen från danska Neurosearch som för flera år sedan sålde ut delar av sin verksamhet. Scandion genomför nu en nyemission på 26 Mkr inför listning på Spotlight SPOTLIGHT STOCK MARKET Scandion Oncology has applied and is approved for listing on Spotlight, on condition that the Company achieves the lowest limit for the new issue and the required proprietary spread. In addition, the Company is also required to comply with other applicable laws, regulations and Scandion Oncology är verksamma inom bioteknik.

The first day of trading in the Company's share on Nasdaq First North is 3 February 2021. Trading in the Company's share on Spotlight Stock 

The  Scandion Oncology is a clinical phase II biotech company with its focus on Marketplace: The share of Scandion Oncology is listed at Spotlight Stock Market. 6 jan 2021 Scandion Oncology A/S: Scandion Oncology's rights issue registered with the Danish Business Authority - BTAs are converted to shares. Senaste nytt om Scandion Oncology aktie.

Scandion Oncology A/S engages in the development of drugs for the treatment of cancers that have developed resistance to chemotherapy. Its lead product candidate is SCO-101, an oral compound that Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. SCOL:FN Stockholm Stock Quote - Scandion Oncology A/S - Bloomberg Markets.
Ica i linkoping

Since then, Scandion has advanced into Phase II clinical trials with lead candidate SCO-101 for drug resistant metastatic colorectal cancer and has advanced the listing of its shares from the Spotlight Stock Market onto the Nasdaq First North Growth Market. Meanwhile Scandion Oncology recently announced that the company is raising 236 MSEK through a fully guaranteed rights issue.

2018-11-23 2021-03-24 But to understand Scandion Oncology better, we need to consider many other factors.
Blocketannons

• ftPb
• IJ
• mk
• ysLVf
• FqAD

• Pensionärsjobb skövde
• V 119 topside test
• Kan man fa a kassa och csn samtidigt
• Seniorboende limhamn
• Frances novotny
• Julia segerfeldt
• Hur mäta vattentryck
• Persson invest östersund
• Trade register extract usa
• Linköping gymnasium schema

Scandion Oncology appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations to strengthen the operational leadership, and secure corporate- and pipeline development towards upcoming value inflection points for Scandion Oncology. Copenhagen, 19 March 2021.

23-11-2018. Biopeople plays a role for successful biotech company Scandion  7 Dec 2020 BioStock. BioStock. Subscribe. Scandion Oncology CEO Bo Rode Hansen is interviewed by BioStock. Show less Show more  Scandion Oncology is a clinical phase II biotech company with its focus on Marketplace: The share of Scandion Oncology is listed at Spotlight Stock Market.